Orforglipron is a groundbreaking, once-daily oral non-peptide small-molecule GLP-1 receptor agonist designed to revolutionize the management of obesity and type 2 diabetes. Unlike traditional peptide-based therapies that require sub-cutaneous injections, Orforglipron offers high oral bioavailability and can be taken without strict food or water restrictions.
Orforglipron(CAS 2212020-52-3)Weight loss,Cardioprotection Peptides
$100.00
Orforglipron (sold under the brand name Foundayo) is a once-daily, oral, small-molecule GLP-1 receptor agonist developed by Eli Lilly and Company for chronic weight management and type 2 diabetes.
Be the first to review “Orforglipron(CAS 2212020-52-3)Weight loss,Cardioprotection Peptides”
Reviews
There are no reviews yet.